Medication info
New Pio Tablets (Pioglitazone Hydrochloride)

New Pio Tablets (Pioglitazone Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Hana Pharm Co., Ltd.
Appearance
White to off-white round tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200906578 · Notified 2009.08.27 · Insurance code 657803970

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
This medicine is administered orally once daily, regardless of meals. Glycated hemoglobin reflects blood glucose control over the preceding 2 ~ 3 months. Clinically, this medicine should be administered for an appropriate period to assess changes in glycated hemoglobin (at least 3 months), provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this medicine does not provide an adequate effect, the dose may be increased to up to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylurea: This medicine may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and regimen. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be continued when starting combination therapy with this medicine. However, in patients receiving this medicine in combination with insulin, if symptoms of hypoglycemia occur or plasma glucose concentration decreases to 100 mg/dL or less, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (refer to the Renal Impairment subsection under General Precautions). Do not initiate treatment with this medicine if the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal) at the start of therapy (refer to Effects on the Liver under Adverse Reactions and General Precautions).
Child dose
Under 18 years: Use is not recommended because there is no experience with its use.

Ingredients

Manufacturer
Hana Pharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Disorder of blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used in conjunction with diet and exercise to assist in the blood sugar control of patients with type 2 diabetes. It can also be administered as monotherapy and is used in combination with sulfonylureas, metformin, or insulin when blood sugar improvement is insufficient with other oral hypoglycemic agents. Additionally, patients are recommended to have nutritional counseling, weight loss, and exercise therapy to aid in the initial treatment and maintenance of drug efficacy. This medication effectively improves blood sugar control.

How to take

Adult dose

This medicine is administered orally once daily, regardless of meals. Glycated hemoglobin reflects blood glucose control over the preceding 2 ~ 3 months. Clinically, this medicine should be administered for an appropriate period to assess changes in glycated hemoglobin (at least 3 months), provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this medicine does not provide an adequate effect, the dose may be increased to up to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylurea: This medicine may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and regimen. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be continued when starting combination therapy with this medicine. However, in patients receiving this medicine in combination with insulin, if symptoms of hypoglycemia occur or plasma glucose concentration decreases to 100 mg/dL or less, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (refer to the Renal Impairment subsection under General Precautions). Do not initiate treatment with this medicine if the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal) at the start of therapy (refer to Effects on the Liver under Adverse Reactions and General Precautions).

Child dose

Under 18 years: Use is not recommended because there is no experience with its use.

Precautions

This medication is used for the treatment of type 2 diabetes and helps in the action of insulin. It may place additional strain on the heart during use, so patients with congestive heart failure or a history of congestive heart failure should not take it. During the initial dosage or after increasing the dose, carefully observe for sudden weight gain, shortness of breath, and swelling. If these symptoms occur, consult a physician immediately for appropriate treatment, and if necessary, discontinue or reduce the dosage. This medication may cause fluid retention leading to swelling, and caution is especially needed for patients with heart disease. Patients with active bladder cancer or a history of bladder cancer should not take this medication. Patients with severely impaired liver or kidney function should also avoid using this medication. Women who are pregnant or may become pregnant should not use this medication, and premenopausal women should employ appropriate contraceptive methods as the risk of pregnancy may increase while taking this medication. Hypoglycemic symptoms may occur when taken with other hypoglycemic agents, so caution is advised, and dosage adjustments for other medications may be necessary. Regular monitoring of blood sugar and liver function tests is required during the use of this medication, and any unusual symptoms such as weight changes, swelling, or shortness of breath should be reported to a physician. Furthermore, long-term use of this medication may lead to weight gain and increased risk of fractures, so consistent management is necessary. Acute overdose may not present any specific symptoms; however, if unusual symptoms occur, consult healthcare professionals immediately. Lastly, this medication has not established safety and efficacy for use in children or adolescents under 18 years of age, so it should not be used.

Side effects

  • Congestive heart failure
  • excessive and rapid weight change
  • dyspnea
  • edema
  • fluid retention
  • edema
  • upper respiratory tract infection
  • headache
  • sinusitis
  • myalgia
Show 56 more
  • pharyngitis
  • abdominal distension
  • weight gain
  • hypoglycemia
  • urinary tract infection
  • low back pain
  • dizziness
  • increased serum creatine kinase
  • hypertension
  • heart failure
  • limb pain
  • chest pain
  • heart function loss
  • orthostatic hypotension
  • palpitations
  • stroke
  • sexual dysfunction
  • myocardial infarction
  • increased blood sugar
  • loss of appetite
  • constipation
  • upper abdominal pain
  • chest pain
  • fatigue
  • weakness
  • dyspepsia
  • nausea
  • dyspnea
  • itching
  • chest discomfort
  • tremors
  • chills
  • gastrointestinal disease
  • abdominal pain
  • epigastric discomfort
  • numbness
  • muscle rigidity
  • head discomfort
  • increased liver enzymes
  • worsening of liver disease
  • urticaria
  • eczema
  • arthralgia
  • knee abnormalities
  • arm weakness
  • proteinuria
  • increased serum creatinine
  • anxiety
  • insomnia
  • drowsiness
  • simple herpes
  • blurred vision
  • low back pain
  • diarrhea
  • macular edema
  • bladder cancer

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a container that is protected from light and air, avoiding humid areas, and kept at a temperature between 15 to 30 degrees Celsius. Storing it this way will help maintain its efficacy over time.

Appearance and packaging

Appearance

White to off-white round tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.